Experienced in Myoclonic Epilepsy Associated With Ragged Red Fibers

Hirofumi Komaki

Tokyo, JP 
Experienced in Myoclonic Epilepsy Associated With Ragged Red Fibers
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Hirofumi Komaki practices in Tokyo, Japan. Komaki is rated as an Experienced expert by MediFind in the treatment of Myoclonic Epilepsy Associated With Ragged Red Fibers. Their top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Danon Disease, and Walker-Warburg Syndrome.

Their clinical research consists of co-authoring 159 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Myoclonic Epilepsy Associated With Ragged Red Fibers.

Locations

Tokyo, Japan
Other Locations
Kodaira, Japan
Japan
Nagoya, Japan
Utsunomiya, 3291193, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3

159 Total Publications

Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.
Journal: Journal of comparative effectiveness research
Published: August 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Komaki's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile